Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Appointed CFO
Quarterly results
Acq. announced
Director departure
CC transcript

ACHIEVE LIFE SCIENCES, INC. (ACHV) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "Achieve Life Sciences Reports Financial Results for Second Quarter 2023 and Provides Corporate Update Company to host conference call tomorrow, Tuesday, August 15, 2023, at 8:30 AM EDT SEATTLE, Wash and VANCOUVER, British Columbia, August 14, 2023 — Achieve Life Sciences, Inc. , a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced second quarter 2023 financial results and provided an update on the cytisinicline development program. Recent Highlights • Publication of Phase 3 ORCA-2 trial results in the Journal of the American Medical Association • Reported statistically significant smoking cessation benefit for cytisinicline in the confirmatory Phase 3 ORCA-..."
05/09/2023 8-K Quarterly results
Docs: "Consolidated Statements of Loss Three months ended March 31, 2023 2022 Operating expenses: Research and development 5,534 4,388 General and administrative 3,044 2,838 Total operating expenses 8,578 7,226 Loss from operations Other income Net loss $ $ Basic and diluted net loss per share $ $ Weighted average number of basic and diluted common shares 17,917,769 9,458,745 Consolidated Balance Sheets March 31, December 31, 2023 2022 Assets: Cash and cash equivalents $ 16,514 $ 24,771 Prepaid expenses and other current assets 1,710 2,559 Other assets and restricted cash 68 123 Right-of-use assets 109 66 License agreement 1,363 1,418 Goodwill 1,034 1,034 Total assets $ 20,798 $ 29,971 Liabilities and stockholders' equity: Accounts payable and accrued liabilities $ 3,872 $ 5,470 Current portion..."
03/16/2023 8-K Quarterly results
Docs: "Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2022 and Provides Corporate Update Company to host conference call March 16, 2023, at 4:30 PM EST"
11/14/2022 8-K Quarterly results
Docs: "Achieve Reports Financial Results for Third Quarter 2022 and Provides Corporate Update Company to host conference call at 4:30 PM EST today, November 14, 2022"
08/11/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/10/2022 8-K Quarterly results
11/09/2021 8-K Quarterly results
Docs: "Achieve Reports Financial Results for Third Quarter 2021 and Provides Update on Cytisinicline Development"
05/13/2021 8-K Quarterly results
03/11/2021 8-K Quarterly results
11/12/2020 8-K Quarterly results
Docs: "Achieve Reports Financial Results for Third Quarter 2020 and Provides Corporate and Cytisinicline Development Update"
08/06/2020 8-K Quarterly results
05/14/2020 8-K Quarterly results
03/13/2020 8-K Quarterly results
11/06/2019 8-K Quarterly results
08/08/2019 8-K Quarterly results
Docs: "Achieve Reports Financial Results for Second Quarter 2019 and Provides Cytisinicline Clinical Development Update"
05/15/2019 8-K Quarterly results
Docs: "Achieve Reports Financial Results for First Quarter 2019 and Provides Cytisinicline Clinical Development Update"
03/14/2019 8-K Quarterly results
Docs: "Achieve Reports Financial Results for Year-End 2018 and Provides Cytisinicline Clinical Development Update"
08/08/2018 8-K Quarterly results
Docs: "Achieve Reports Financial Results for Second Quarter 2018 and Provides Cytisine Clinical Development Update"
11/09/2017 8-K Quarterly results
Docs: "Achieve Reports Financial Results for Third Quarter 2017"
05/15/2017 8-K Form 8-K - Current report
02/23/2017 8-K Form 8-K - Current report
11/10/2016 8-K Quarterly results
Docs: "OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2016"
08/04/2016 8-K Quarterly results
Docs: "OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2016 Pivotal Phase 3 Prostate Trial Results Expected in Third Quarter 2016"
05/12/2016 8-K Form 8-K - Current report
03/09/2016 8-K Quarterly results
Docs: "OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Year End 2015 Conference call to be held on Wed., March 9, 2016 at 4:30 p.m. Eastern Time"
11/12/2015 8-K Quarterly results
Docs: "OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2015 Conference call to be held on Thursday, November 12, 2015 at 4:30 p.m. Eastern Time"
08/13/2015 8-K Quarterly results
Docs: "OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2015 Conference call to be held on Thursday, August 13, 2015 at 4:30 p.m. Eastern Time"
05/14/2015 8-K Quarterly results
Docs: "OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2015"
03/26/2015 8-K Quarterly results
Docs: "OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 Conference call to be held on Thursday, March 26, 2015 at 4:30 p.m. Eastern Time BOTHELL, WA, and VANCOUVER, British Columbia, March 26, 2015 - OncoGenex Pharmaceuticals, Inc. today provided a summary of clinical developments and announced fourth quarter and year end 2014 financial results. Clinical Developments and Anticipated Near-term Milestones"
10/30/2014 8-K Quarterly results
Docs: "OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2014 Conference call to be held on Thursday, October 30, 2014 at 4:30 p.m. Eastern Time BOTHELL, WA, and VANCOUVER, British Columbia, October 30, 2014 - OncoGenex Pharmaceuticals, Inc. today provided a summary of clinical developments and announced third quarter 2014 financial results. Q3 2014 Highlights"
08/07/2014 8-K Quarterly results
Docs: "Employment Agreement between OncoGenex Pharmaceuticals, Inc. and John Bencich",
"OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2014 Conference call to be held on Thursday, August 7, 2014 at 4:30 p.m. Eastern Time BOTHELL, WA, and VANCOUVER, British Columbia, August 7, 2014 - OncoGenex Pharmaceuticals, Inc. today provided a summary of clinical developments and announced second quarter 2014 financial results. Clinical Developments and Anticipated Milestones",
"OncoGenex Pharmaceuticals Announces Appointment of John A. Bencich as Vice President and Chief Financial Officer BOTHELL, WA, and VANCOUVER, British Columbia, August 7, 2014"
04/30/2014 8-K Quarterly results
Docs: "OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2014 Conference call to be held on Wednesday, April 30, 2014 at 4:30 p.m. Eastern Time BOTHELL, WA, and VANCOUVER, British Columbia, April 30, 2014 - OncoGenex Pharmaceuticals, Inc. today provided a summary of clinical developments and anticipated near-term milestones and announced first quarter 2014 financial results. Clinical Developments and Anticipated Near-term Milestones"
03/11/2014 8-K Quarterly results
Docs: "OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2013 Conference call to be held on Tuesday, March 11, 2014 at 4:30 p.m. Eastern Time BOTHELL, WA, and VANCOUVER, British Columbia, March 11, 2014 - OncoGenex Pharmaceuticals, Inc. today provided a summary of clinical developments and anticipated near-term milestones and announced fourth quarter and year end 2013 financial results. Clinical Developments and Anticipated Near-term Milestones"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy